Response to Comments: MolDX: Melanoma Risk Stratification Molecular Testing

This document (A59084) records responses to public comments on the MolDX Melanoma Risk Stratification Molecular Testing LCD (L38016) and provides comment, notice, and effective dates. It does not itself establish clinical coverage, limitations, documentation requirements, or frequency limits; providers must consult the final LCD L38016 (effective 2022-07-03) for actionable coverage criteria.

"This document is a response to public comments and does not itself define or change coverage criteria for melanoma risk stratification molecular testing; coverage is determined by LCD L38016 when e..."

Sign up to see full coverage criteria, indications, and limitations.